These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34430070)

  • 1. Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray.
    Schwittay MA; Steinbrecher A; Lobsien E
    Tremor Other Hyperkinet Mov (N Y); 2021; 11():33. PubMed ID: 34430070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.
    Szejko N; Saramak K; Lombroso A; Müller-Vahl K
    Neurol Neurochir Pol; 2022; 56(1):28-38. PubMed ID: 34708399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients.
    Jakubovski E; Müller-Vahl K
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders.
    Jakubovski E; Pisarenko A; Fremer C; Haas M; May M; Schumacher C; Schindler C; Häckl S; Aguirre Davila L; Koch A; Brunnauer A; Cimpianu CL; Lutz B; Bindila L; Müller-Vahl K
    Front Psychiatry; 2020; 11():575826. PubMed ID: 33324255
    [No Abstract]   [Full Text] [Related]  

  • 5. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.
    Müller-Vahl KR; Pisarenko A; Szejko N; Haas M; Fremer C; Jakubovski E; Musil R; Münchau A; Neuner I; Huys D; van Elst LT; Schröder C; Ringlstetter R; Koch A; Jenz EB; Großhennig A
    Psychiatry Res; 2023 May; 323():115135. PubMed ID: 36878177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tics and Gilles de la Tourette syndrome].
    Tijero-Merino B; Gómez-Esteban JC; Zarranz JJ
    Rev Neurol; 2009 Jan; 48 Suppl 1():S17-20. PubMed ID: 19222010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols.
    Kanaan AS; Jakubovski E; Müller-Vahl K
    Brain Sci; 2017 Apr; 7(5):. PubMed ID: 28445405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe motor and vocal tics controlled with Sativex®.
    Trainor D; Evans L; Bird R
    Australas Psychiatry; 2016 Dec; 24(6):541-544. PubMed ID: 27558217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin for motor and phonic tics in Tourette's syndrome.
    Pandey S; Srivanitchapoom P; Kirubakaran R; Berman BD
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD012285. PubMed ID: 29304272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study.
    Lasch F; Guizzaro L; Aguirre Dávila L; Müller-Vahl K; Koch A
    Pharm Stat; 2021 May; 20(3):675-691. PubMed ID: 33594741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for tics in adult patients with Tourette syndrome and other tic disorders.
    Badenoch J; Cavanna AE
    Neurol Sci; 2020 Jul; 41(7):1923-1926. PubMed ID: 32170503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.
    Müller-Vahl KR; Schneider U; Prevedel H; Theloe K; Kolbe H; Daldrup T; Emrich HM
    J Clin Psychiatry; 2003 Apr; 64(4):459-65. PubMed ID: 12716250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dystonic motor and phonic tics in Tourette syndrome.
    Baizabal-Carvallo JF; Alonso-Juarez M; Jankovic J
    J Neurol; 2022 Oct; 269(10):5312-5318. PubMed ID: 35567613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine in Gilles de la Tourette syndrome: beyond tics.
    Van den Eynde F; Naudts KH; De Saedeleer S; van Heeringen C; Audenaert K
    Acta Neurol Belg; 2005 Dec; 105(4):206-11. PubMed ID: 16482870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal relationship between premonitory urges and tics in Gilles de la Tourette syndrome.
    Brandt VC; Beck C; Sajin V; Baaske MK; Bäumer T; Beste C; Anders S; Münchau A
    Cortex; 2016 Apr; 77():24-37. PubMed ID: 26922503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey.
    Milosev LM; Psathakis N; Szejko N; Jakubovski E; Müller-Vahl KR
    Cannabis Cannabinoid Res; 2019; 4(4):265-274. PubMed ID: 31872061
    [No Abstract]   [Full Text] [Related]  

  • 17. Type IIB thyroplasty for phonic tics in a pediatric patient with autism spectrum disorder: a case report.
    Ahmed MM; Heckman WW; Dailey SH
    J Voice; 2013 Mar; 27(2):242-4. PubMed ID: 23406841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct structural changes underpin clinical phenotypes in patients with Gilles de la Tourette syndrome.
    Worbe Y; Gerardin E; Hartmann A; Valabrégue R; Chupin M; Tremblay L; Vidailhet M; Colliot O; Lehéricy S
    Brain; 2010 Dec; 133(Pt 12):3649-60. PubMed ID: 20959309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome.
    Pappert EJ; Goetz CG; Louis ED; Blasucci L; Leurgans S
    Neurology; 2003 Oct; 61(7):936-40. PubMed ID: 14557563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Tourette syndrome with cannabinoids.
    Müller-Vahl KR
    Behav Neurol; 2013; 27(1):119-24. PubMed ID: 23187140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.